Crossmark

Development of a predictive model for pathological complete response following neoadjuvant immunotherapy and chemotherapy in locally advanced resectable esophageal squamous cell carcinoma

Crossref DOI link: https://doi.org/10.1186/s12957-026-04275-w

Published Online: 2026-02-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Yilei

Xie, Hounai

Zhang, Deguo

Liu, Yujuan

Fu, Shuaiming

Yu, Yongkui

Ma, Wei
Funding

Funding for this research was provided by:

Natural Science Foundation of Shandong Province (ZR2023QH558)
License Information

Text and Data Mining valid from 2026-02-25

Version of Record valid from 2026-04-01
More Information

Article History

Received: 28 November 2025

Accepted: 19 February 2026

First Online: 25 February 2026

Declarations

:

: The study was approved by the Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China (approval number: 2025 − 706; approval date: October 20, 2025) and was performed in accordance with the 1964 Declaration of Helsinki and its later revisions. The requirement for informed consent was waived.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below